Treating Thought Problems in Patients With Schizophrenia - Full Text View

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00051740

Purpose

This study will compare Cognitive Adaptation Training (CAT) to minimal schizophrenia treatment. This study will also determine whether the intensity of CAT can be reduced and still provide benefits to patients with schizophrenia.

Condition	Intervention
Schizophrenia	Behavioral: Cognitive Adaptation Therapy (CAT) Behavioral: Minimal Environmental Supports (MES)

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Compensating for Cognitive Deficits in Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	120
Study Start Date:	February 2002

Detailed Description:

Many schizophrenia patients have serious difficulties that affect their quality of life. Cognitive Adaptation Training (CAT) may improve adaptive functioning, quality of life, and rates of relapse in schizophrenia patients. CAT, which involves compensatory strategies or environmental supports, is tailored to each individual and is based on executive functioning levels and other factors.

Participants are randomly assigned to CAT, Minimal Environmental Supports (MES), or treatment as usual for 2 years. Participants receiving CAT will have a trained therapist make weekly visits to their home for 9 months. Over the following 3 months, the frequency of CAT visits will be slowly reduced to once a month. For the remaining 12 months of treatment, patients receive CAT only once a month.

Participants assigned to the MES group receive a generic set of supplies and equipment (calendar, alarm clock, watch, bus passes, etc.) at the beginning of the 2-year period. Each month, the supplies are replenished as necessary during the patient's scheduled clinic visit.

In all groups, assessments of adaptive function and quality of life occur at study start and at 3, 6, 9, 18, and 24 months.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

DSM-IV diagnosis of schizophrenia or schizoaffective disorder
Treatment with an atypical antipsychotic medication
Stable living environment
Able to read, understand, and complete rating scales and neuropsychological testing
Willing to participate in psychosocial treatments for schizophrenia that may involve home visits

Exclusion Criteria:

History of significant head trauma, seizure disorder, or mental retardation
Alcohol or drug abuse that could interfere with participation in the study
Treatment by an ACT team
History of violence in the past year
Score > 80 on the SOFAS
Hospitalized in the past year

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051740

Locations

United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

Principal Investigator:

Dawn I. Velligan, Ph.D.

University of Texas

More Information

No publications provided

Study ID Numbers:	R01 MH61775, DATR A4-GPS
Study First Received:	January 15, 2003
Last Updated:	November 29, 2005
ClinicalTrials.gov Identifier:	NCT00051740 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 27, 2009